Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Kontinuerlig dobbelt aspirations-teknik med Zoom-system til slagtilfælde (ADAPT 2 0)

11. november 2026 opdateret af: Imperative Care, Inc.

Klinisk evaluering af kontinuerlig dobbeltaspirationsteknik med Zoom-system til apopleksi (ADAPT 2.0)

This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Observationel

Tilmelding (Anslået)

750

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Alabama
      • Huntsville, Alabama, Forenede Stater, 35801
        • Rekruttering
        • Huntsville Hospital
        • Kontakt:
          • Farrar Hickey
        • Ledende efterforsker:
          • R. Dana Tomalty, MD
    • California
      • Walnut Creek, California, Forenede Stater, 94598
        • Rekruttering
        • John Muir Health
        • Ledende efterforsker:
          • Benjamin Yim, MD
        • Kontakt:
          • Melenie Aaron
    • Florida
      • Tampa, Florida, Forenede Stater, 33606
        • Rekruttering
        • University of South Florida
        • Ledende efterforsker:
          • Maxim Mokin, MD
        • Kontakt:
          • Kilaun Robinson
    • Georgia
      • Marietta, Georgia, Forenede Stater, 30060
        • Rekruttering
        • Wellstar Kennestone Hospital
        • Kontakt:
          • Autumn Lee
        • Ledende efterforsker:
          • Ahmad Khaldi, MD
    • Louisiana
      • Lafayette, Louisiana, Forenede Stater, 70503
        • Rekruttering
        • Ochsner Clinic Foundation (Lafayette)
        • Ledende efterforsker:
          • Shail Thanki, MD
      • New Orleans, Louisiana, Forenede Stater, 70121
        • Rekruttering
        • Ochsner Clinic Foundation
        • Ledende efterforsker:
          • James Milburn, MD
        • Kontakt:
          • Jessica Henry
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21201
        • Rekruttering
        • University of Maryland
        • Ledende efterforsker:
          • Jacob Cherian, MD
        • Kontakt:
          • Katie Henry
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55407
        • Rekruttering
        • Allina Health
        • Kontakt:
          • Emeryth Beloy
        • Ledende efterforsker:
          • Collin Torok, MD
    • New York
      • Albany, New York, Forenede Stater, 12208
        • Rekruttering
        • Albany Medical College
        • Ledende efterforsker:
          • Alexandra Paul, MD
        • Kontakt:
          • Chelsey Large
      • Buffalo, New York, Forenede Stater, 14203
        • Rekruttering
        • University at Buffalo Neurosurgery
        • Ledende efterforsker:
          • Jason Davies, MD
        • Kontakt:
          • Ellen Carl
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • Weill Cornell Medicine
        • Kontakt:
          • Hanah Hwang
        • Ledende efterforsker:
          • Amol Mehta, MD
      • New York, New York, Forenede Stater, 10029
        • Rekruttering
        • Icahn School of Medicine at Mount Sinai
        • Kontakt:
          • Kevin Buttet
        • Ledende efterforsker:
          • Michael T Caton, MD
      • Syracuse, New York, Forenede Stater, 13210
        • Rekruttering
        • SUNY Upstate Medical Center
        • Kontakt:
          • Saptarshi Prachi
        • Ledende efterforsker:
          • Haydn Hoffman, MD
      • The Bronx, New York, Forenede Stater, 10467
        • Rekruttering
        • Montefiore Medical Center
        • Kontakt:
          • Genesis Liriano
        • Ledende efterforsker:
          • Amanda Baker, MD
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45220
        • Rekruttering
        • TriHealth Good Samaritan Hospital
        • Ledende efterforsker:
          • Andrew Ringer, MD
        • Kontakt:
          • Mehnaaz Ali
      • Columbus, Ohio, Forenede Stater, 43221
        • Rekruttering
        • The Ohio State University Wexner Medical Center
        • Ledende efterforsker:
          • Patrick Youssef, MD
        • Ledende efterforsker:
          • Shahid Nimjee, MD
        • Kontakt:
          • Edward Belizaire
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Rekruttering
        • University of Oklahoma, Health Science Center
        • Ledende efterforsker:
          • Hakeem Shakir, MD
        • Kontakt:
          • Sanaa Hameed
    • South Carolina
      • Greenville, South Carolina, Forenede Stater, 29605
        • Rekruttering
        • Prisma Health - Upstate
        • Kontakt:
          • Shawn Manos
        • Ledende efterforsker:
          • Jan Vargas Machaj, MD
    • Tennessee
      • Knoxville, Tennessee, Forenede Stater, 37902
        • Rekruttering
        • Fort Sanders Regional Medical Center
        • Kontakt:
          • Cameron Carter
        • Ledende efterforsker:
          • Robert Hixson, MD
      • Memphis, Tennessee, Forenede Stater, 38120
        • Rekruttering
        • Semmes Murphey Foundation
        • Ledende efterforsker:
          • Lucas Elijovich, MD
        • Kontakt:
          • Wendell Barnett
    • Texas
      • Kingwood, Texas, Forenede Stater, 77339
        • Rekruttering
        • HCA Houston Healthcare Kingwood
        • Ledende efterforsker:
          • Mohamad Ezzeldin, MD
        • Kontakt:
          • Swathi Potla
      • San Antonio, Texas, Forenede Stater, 78229
        • Rekruttering
        • Methodist Healthcare System of San Antonio
        • Kontakt:
          • Samantha Franklin
        • Ledende efterforsker:
          • Lee Birnbaum, MD
      • San Antonio, Texas, Forenede Stater, 78229
        • Rekruttering
        • University of Texas Science Health Center at San Antonio
        • Ledende efterforsker:
          • Justin Mascitelli, MD
        • Kontakt:
          • Athena Lazaris-Conner
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84112
        • Rekruttering
        • University of Utah
        • Kontakt:
          • Andrew Grandemange
        • Ledende efterforsker:
          • Robert Rennert, MD
    • Virginia
      • Falls Church, Virginia, Forenede Stater, 22042
        • Rekruttering
        • Inova Fairfax Medical Campus
        • Kontakt:
          • Lauren Monroe
        • Ledende efterforsker:
          • James McEachern, MD
    • Washington
      • Spokane, Washington, Forenede Stater, 99204
        • Rekruttering
        • Providence Sacred Heart Medical Center and Children's Hospital
        • Kontakt:
          • Kyle Kramer
        • Ledende efterforsker:
          • Christopher Zylak, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Adult subjects with acute ischemic stroke secondary to large vessel occlusion (LVO) meeting the study eligibility criteria and providing written informed consent.

Beskrivelse

Inclusion Criteria:

  1. Subject is ≥ 18 years of age
  2. Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure
  3. Pre-stroke mRS 0-2
  4. Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use

Exclusion Criteria:

  1. Subjects with a life expectancy of less than 6 months
  2. Female subject who is known to be pregnant at time of admission
  3. Any intracranial hemorrhage in the qualifying head CT or MRI
  4. Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).
  5. In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System
  6. Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
ADAPT 2.0: Zoom System with Continuous Dual Aspiration Technique (CDAT)

The Zoom System is intended to be used as the first-line device and utilized within the FDA-cleared indications for use, consistent with the approved labeling and intended anatomical targets.

Aspiration neurothrombectomy using Zoom System with Continuous Dual Aspiration Technique (CDAT)

Andre navne:
  • ADAPT 2.0
  • Aspireringstrombektomi ved apopleksi
  • Kontinuerlig dobbeltsugning
  • Neurovaskulær aspirerende trombektomi

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of patients achieving modified Thrombolysis in Cerebral Infarction (mTICI) score of ≥2c at the end of procedure, as adjudicated by independent core-lab
Tidsramme: End of procedure

mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches

End of procedure
Rate of Embolization to New Territory (ENT) on final angiography at the end of the procedure by investigator assessment
Tidsramme: End of procedure

Embolization to New Territory (ENT), defined as the presence of new occlusions on final angiography that occur in vascular territories remote from those effected by index stroke, as assessed by the investigator

End of procedure

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to achieve mTICI≥2c, defined as groin puncture to investigator assessment for mTICI≥2c
Tidsramme: Intraprocedural

The time from groin puncture to mTICI (modified treatment in cerebral infarction) score ≥ 2c using study device and technique.

mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches

Intraprocedural
Proportion of cases with clot ingestion, as evidenced by clot captured within the Zoom POD
Tidsramme: Intraprocedural

Proportion of cases with clot ingestion, as evidenced by clot captured within at least one of the Zoom PODs

Intraprocedural
Proportion of cases with clot captured within the Zoom POD connected to the outer aspiration catheter
Tidsramme: Intraprocedural

Proportion of cases with clot ingestion, as evidenced by clot captured within the outer Zoom PODs

Intraprocedural
Rate of rescue therapy
Tidsramme: Intraprocedural

Proportion of cases with rescue therapy, defined as unplanned use of another manufacturer's thrombectomy device, angioplasty, or stenting within the target vessel territory to achieve mTICI≥2c.

Intraprocedural
Rate of functional independence (mRS 0-2) at 90 days
Tidsramme: 90 days post-procedure

Proportion of patients achieving mRS (modified Rankin Scale) ≤2 at 90 days

mRS range: 0 to 6; The mRS scale ranges from 0 (no symptoms) to 5 (severe disability), with an additional category of 6 for death; higher score means worse outcome

90 days post-procedure
Proportion of patients achieving First Pass Effect (FPE) mTICI ≥2c as adjudicated by independent core-lab
Tidsramme: Intraprocedural

Proportion of cases achieving First Pass Effect (FPE), defined as mTICI ≥2c after the first pass with the study device and technique as adjudicated by independent core-lab

mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches

Intraprocedural
Rate of symptomatic intracranial hemorrhage (sICH), as confirmed by imaging and independently adjudicated by medical monitor, at the 24-hour post-procedure
Tidsramme: 24-hour post-procedure

Independently adjudicated rate of symptomatic intracranial hemorrhage (sICH) defined as any apparently extravascular blood in the brain or within the cranium confirmed by imaging that is associated with clinical deterioration as defined by an increase of four or more points in the NIHSS at 24 hours compared to the baseline assessment, or that led to death, and was judged to be the predominant cause of a neurologic deterioration or death, per ECASS III criteria

24-hour post-procedure
90-day all-cause mortality
Tidsramme: 90 days post-procedure

Rate of all-cause mortality through 90 days post-procedure

90 days post-procedure
Rate of device-related Serious Adverse Events, independently adjudicated medical monitor
Tidsramme: Intraprocedural

Independently adjudicated rate of Serious Adverse Events related to study device

Intraprocedural

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: David Fiorella, MD, Stony Brook University
  • Ledende efterforsker: Shahram Majidi, MD, Icahn School of Medicine at Mount Sinai
  • Ledende efterforsker: Justin Masciteli, MD, The University of Texas Health Science Center at San Antonio
  • Ledende efterforsker: Maxim Mokin, MD, University of South Florida

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

24. marts 2026

Primær færdiggørelse (Anslået)

31. marts 2030

Studieafslutning (Anslået)

1. juni 2030

Datoer for studieregistrering

Først indsendt

17. marts 2026

Først indsendt, der opfyldte QC-kriterier

24. marts 2026

Først opslået (Faktiske)

25. marts 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • ICI-2025-003

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .